Earnings summaries and quarterly performance for Absci.
Executive leadership at Absci.
Board of directors at Absci.
Research analysts who have asked questions during Absci earnings calls.
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
4 questions for ABSI
Also covers: ABCL, ARWR, AZTA +19 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
4 questions for ABSI
Also covers: CLSD, EYPT, KALV +2 more
Gil Blum
Needham & Company
4 questions for ABSI
Also covers: AUTL, CELC, FATE +9 more
AX
Alexander Xenakis
Truist Securities
3 questions for ABSI
Arseniy Shabashvili
Guggenheim Securities
3 questions for ABSI
Also covers: TVTX
MG
Morgan Gryga
Morgan Stanley
3 questions for ABSI
Also covers: CERT, HALO, SAGE
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for ABSI
Also covers: BSEM, CGEN, CLGN +24 more
GF
George Farmer
Scotiabank
2 questions for ABSI
Also covers: ADAP, INMB, KURA +7 more
SD
Steve Dechert
KeyBanc Capital Markets
2 questions for ABSI
Also covers: ABCL, CERT, LFMD +2 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for ABSI
Also covers: ABCL, AFMD, ARVN +12 more
Vamil Divan
Guggenheim Securities
1 question for ABSI
Also covers: ABBV, ANIP, BHVN +7 more
VP
Vikram Purohit
Morgan Stanley
1 question for ABSI
Also covers: ARGX, ARQT, ASND +11 more
Recent press releases and 8-K filings for ABSI.
Absci Unveils New AI Model and Provides Clinical Pipeline Updates
ABSI
Product Launch
New Projects/Investments
Guidance Update
- Absci announced the release of its new generative AI model, Origin-1, designed for the de novo creation of antibodies targeting novel, hard-to-drug epitopes.
- The company anticipates two Phase II readouts within the next 24 months for its AI-designed molecules, ABS-101 and ABS-201, targeting androgenic alopecia and endometriosis.
- For ABS-201 in androgenic alopecia, a Phase I/II-A study is underway, with a safety readout expected in the first half of 2026 and a 13-week efficacy readout in the second half of 2026. The U.S. total addressable market for this program is estimated at over $25 billion annually.
- Absci plans to initiate a Phase II trial for ABS-201 in endometriosis in Q4 2026, with a proof-of-concept readout expected a year later.
- As of the end of 2025, Absci's balance sheet held $143 million, providing a cash runway into the first half of 2028.
Jan 14, 2026, 11:45 PM
Absci Announces New AI Model Origin One and Provides Clinical Pipeline Updates
ABSI
Product Launch
New Projects/Investments
Guidance Update
- Absci released its new Origin One AI model for de novo antibody design, enabling targeting of hard-to-drug epitopes and application to its early-stage pipeline.
- The company anticipates a safety readout in H1 2026 and a 13-week efficacy readout in H2 2026 for its ABS-201 androgenic alopecia program, with a Phase 2 proof-of-concept readout for endometriosis expected in Q4 2027.
- As of the end of 2025, Absci's balance sheet stood at $143 million, providing a cash runway into the first half of 2028.
- The estimated total addressable market for ABS-201 in androgenic alopecia is projected to exceed $25 billion annually in the U.S. and $40 billion worldwide.
Jan 14, 2026, 11:45 PM
Absci Presents Pipeline Progress and Financial Outlook at J.P. Morgan Healthcare Conference
ABSI
New Projects/Investments
Product Launch
- Absci reported a balance sheet of over $143 million as of December 31, 2025, providing a runway into the first half of 2028.
- The company is advancing three clinical-stage programs, including ABS-201 for Androgenetic Alopecia (AGA) and Endometriosis, and ABS-101 for Inflammatory Bowel Disease (IBD).
- Key catalysts for ABS-201 in AGA include PK and interim safety readouts expected in 1H 2026, with an interim Proof-of-Concept (PoC) readout anticipated in 2H 2026. Phase 2 initiation for ABS-201 in Endometriosis is also expected in 2H 2026.
- ABS-201 for Endometriosis has the potential to generate over $4.5 billion in peak sales.
Jan 14, 2026, 11:45 PM
Absci Corporation provides business update at J.P. Morgan Healthcare Conference
ABSI
New Projects/Investments
Guidance Update
- Absci Corporation presented a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
- The company has three clinical-stage programs: ABS-201 for Androgenetic Alopecia (AGA) and Endometriosis (both Phase 1/2a), and ABS-101 for Inflammatory Bowel Disease (IBD) (Phase 1 and partnering ready).
- For ABS-201 in AGA, the Phase 1/2a study began in December 2025, with PK and interim safety data expected in 1H 2026 and an interim Proof-of-Concept readout anticipated in 2H 2026. The estimated U.S. Total Addressable Market (TAM) for AGA is >$25 billion.
- ABS-201 in Endometriosis, also initiated Phase 1/2a in December 2025, has a potential for >$4.5 billion in peak sales, with Phase 2 initiation expected in 2H 2026.
- As of December 31, 2025, Absci reported >$143 million in cash, cash equivalents, and marketable securities, providing a cash runway into 1H 2028.
Jan 14, 2026, 10:27 PM
ABSI Initiates Phase 1/2a Trial for ABS-201 in Androgenetic Alopecia
ABSI
Product Launch
New Projects/Investments
- ABSI is developing ABS-201, a drug candidate for androgenetic alopecia (AGA) in both men and women, which aims to address the root cause of hair loss by blocking PRLR signaling.
- Preclinical studies for ABS-201 demonstrated superior efficacy compared to 5% topical minoxidil in a 21-day hair regrowth model and showed significant increases in thick hairs in bald areas in a primate model. Human ex vivo scalp skin data also indicates ABS-201 prolongs the anagen phase, inhibits catagen, and promotes hair follicle stem cells and key hair growth factors.
- A Phase 1/2a clinical trial for ABS-201 was initiated in December 2025 in Australia, designed to assess safety, tolerability, and proof-of-concept in AGA subjects.
- Key readouts from the clinical trial are anticipated in 1H 2026 for PK and interim safety from the Single Ascending Dose (SAD) cohorts, 2H 2026 for the 13-week interim Proof-of-Concept (PoC) from Multiple Ascending Dose (MAD) cohorts, and early 2027 for the 26-week topline PoC readout.
- The company estimates a U.S. total addressable market (TAM) of 80 million patients and a potential global TAM of >$40 billion for AGA, with market research indicating high interest in ABS-201's target product profile.
Dec 11, 2025, 3:00 PM
Absci Initiates Phase 1/2a Clinical Trial for Hair Loss Drug ABS-201
ABSI
New Projects/Investments
Product Launch
- Absci has developed ABS-201, an optimized prolactin receptor antibody for hair loss, leveraging its AI platform, which demonstrated compelling preclinical efficacy and a favorable safety profile.
- A Phase 1/2a clinical trial for ABS-201 has commenced, with the first participant dosed this month, and an interim efficacy readout is anticipated in the second half of 2026.
- The company projects a significant market opportunity for ABS-201, with an estimated total available market of greater than $25 billion in the U.S. and greater than $40 billion globally, targeting potential FDA approval by 2029 or 2030.
- ABS-201 is designed for convenient subcutaneous application, potentially every two to three months, aiming to address the high unmet need for effective and durable hair loss treatments.
Dec 11, 2025, 3:00 PM
Absci Initiates Clinical Trial for ABS-201 Androgenetic Alopecia Treatment
ABSI
New Projects/Investments
- Absci has initiated a Phase 1/2a clinical trial for ABS-201, a generative AI-designed biologic aimed at treating androgenetic alopecia (hair loss) by targeting the prolactin receptor pathway.
- The company has dosed its first participant in the trial, which will assess safety, tolerability, and efficacy.
- An interim efficacy readout from the Phase 1/2a trial is expected in the second half of 2026, with a 26-week readout anticipated in early 2027.
- Absci estimates a total available market in the U.S. of greater than $25 billion and a potential global market of greater than $40 billion for ABS-201, based on an estimated 15-18 million patients with high interest and willingness to pay premium pricing.
Dec 11, 2025, 3:00 PM
Absci Initiates Phase 1/2a Trial for ABS-201, Targeting $25B+ Hair Loss Market
ABSI
New Projects/Investments
Product Launch
- Absci has initiated its Phase 1/2a clinical trial for ABS-201, a generative AI-designed prolactin receptor antibody intended to treat androgenetic alopecia, with the first participant already dosed this month.
- The double-blinded, placebo-controlled trial aims to enroll up to 227 participants to assess safety, tolerability, and hair growth efficacy over 26 weeks.
- An interim efficacy readout is anticipated in Q3, Q4 2026, with the full 26-week readout expected in early 2027.
- Market research indicates a significant unmet medical need, with 80% of men and 81% of women reporting strong negative psychological impacts from hair loss.
- The estimated total available market for ABS-201 in the U.S. is greater than $25 billion, with a global potential exceeding $40 billion, and potential FDA approval projected for 2029 or 2030.
Dec 11, 2025, 3:00 PM
Absci Corporation Provides Update on AI Drug Discovery Pipeline and Financials at 2025 Healthcare Conference
ABSI
Guidance Update
New Projects/Investments
- Absci, an AI-driven generative design company, is advancing its lead asset, ABS-201, an anti-prolactin receptor antibody, for androgenic alopecia (AGA) and endometriosis.
- The company expects two phase two readouts for ABS-201 in AGA and endometriosis within the next 24 months. The phase one two-way study for AGA will begin in December 2025, with the first efficacy interim readout anticipated in the second half of 2026.
- As of Q3, Absci reported $150 million on its balance sheet, providing a cash runway into the first part of 2028.
- Absci has strategic partnerships with companies like AstraZeneca, Merck, NVIDIA, and AMD, with AMD recently investing $20 million and becoming a top shareholder.
- The company projects potential peak sales greater than $5 billion for ABS-201 in endometriosis, citing a large unmet medical need and poor standard of care.
Nov 18, 2025, 9:30 AM
Absci Highlights ABS-201 Clinical Progress and Financial Runway
ABSI
New Projects/Investments
Guidance Update
- Absci expects two phase two readouts for its lead asset, ABS-201, in androgenic alopecia (AGA) and endometriosis within the next 24 months. The phase one two-way study for ABS-201 in AGA is set to begin in December 2025, with the first efficacy interim readout anticipated in the second half of 2026.
- The company reported $150 million on its balance sheet as of Q3, providing a cash runway into the first part of 2028.
- Absci has strategic partnerships, including a $20 million investment from AMD, which is also a top shareholder, and collaborations with AstraZeneca, Merck, and NVIDIA.
- The potential market for ABS-201 in endometriosis is significant, with estimated peak sales of greater than $5 billion for a disease-modifying treatment.
Nov 18, 2025, 9:30 AM
Quarterly earnings call transcripts for Absci.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more